Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Investigation of the Effect of Vorinostat (VOR) on HIV RNA Expression in the Resting CD4+ T Cells of HIV-Infected Patients Receiving Stable Antiretroviral Therapy.

Next Previous
Trial Profile

A Phase I/II Investigation of the Effect of Vorinostat (VOR) on HIV RNA Expression in the Resting CD4+ T Cells of HIV-Infected Patients Receiving Stable Antiretroviral Therapy.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vorinostat (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use

Most Recent Events

  • 03 Jun 2016 Status changed from recruiting to completed.
  • 02 Oct 2012 The dosage of vorinostat changed from 200-600 mg given at different weeks to 400mg given as single dose, paired dose and multiple dose given at different visits, according to ClinicalTrials.gov
  • 02 Oct 2012 Planned number of patients changed from 20 to 30

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top